SUCAMPO PHARMACEUTICALS, INC.
SCMP evidence brief
What we can confirm
- BioSniper Score:
- 8.0 / 10
- Lead Asset:
- amitiza (Approved)
What it means
What to watch
Prepared research question
What matters most for SCMP—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
amitiza (Approved)
Next Catalyst
—
Tracking 3 pipeline candidates · 1 clinical trial for SUCAMPO PHARMACEUTICALS, INC..
Run SUCAMPO PHARMACEUTICALS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available SUCAMPO PHARMACEUTICALS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Approved
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Frequently asked questions
What is SUCAMPO PHARMACEUTICALS, INC.'s lead drug candidate?
SUCAMPO PHARMACEUTICALS, INC.'s most advanced tracked candidate is amitiza (Approved) for Opioid-induced constipation (OIC) in patients with chronic non-cancer pain.
Who is the CEO of SUCAMPO PHARMACEUTICALS, INC.?
Peter Greenleaf is the chief executive officer of SUCAMPO PHARMACEUTICALS, INC. (SCMP).
What therapeutic areas does SUCAMPO PHARMACEUTICALS, INC. focus on?
SUCAMPO PHARMACEUTICALS, INC. develops therapies across Oncology, Ophthalmology, Cardiovascular, Pain, Gastroenterology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.